News | October 01, 2012

FDA Receives Resubmission of the Apixaban Drug Application to Reduce Stroke in Patients With Atrial Fibrillation

Pfizer Bristol-Myers Squibb Eliquis

October 1, 2012 — Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the new drug application (NDA) resubmission for Eliquis (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) goal date of March 17, 2013. The FDA has deemed the resubmission a complete response to its June 22, 2012 complete response letter that requested additional information on data management and verification from the ARISTOTLE trial.

The Eliquis NDA is based on the results of the ARISTOTLE and AVERROES studies. These clinical studies evaluated Eliquis in approximately 24,000 patients with NVAF, in the largest clinical trial program conducted to date in this patient population. The landmark ARISTOTLE trial compared apixaban to warfarin, the standard of care, in more than 18,000 NVAF patients, while AVERROES compared apixaban to aspirin in 5,598 NVAF patients who were unsuitable for vitamin K antagonist (VKA) therapy.

ARISTOTLE and AVERROES are part of an ongoing clinical development program for Eliquis, which is projected to include nearly 60,000 patients worldwide across multiple indications and patient populations and includes a total of nine completed or ongoing, randomized, double-blind phase III trials.

The companies continue to progress the Eliquis application for stroke prevention in atrial fibrillation in markets outside of the United Stated, including the European Union and Japan, based on the ARISTOTLE and AVERROES studies. On Sept. 21, 2012, Bristol-Myers Squibb and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending that Eliquis (apixaban) be granted approval for the prevention of stroke and systemic embolism in adult patients with NVAF and with one or more risk factors for stroke.

Eliquis is also being investigated in Phase III trials for the treatment of venous thrombolembolic events (VTE).

For more information: www.pfizer.com


Related Content

News | Pharmaceuticals

May 15, 2023 — Cardio Diagnostics Holdings, Inc, a precision cardiovascular medicine company, today announced the ...

Home May 15, 2023
Home
News | Pharmaceuticals

May 2, 2023 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

Home May 02, 2023
Home
News | Pharmaceuticals

April 14, 2023 — A new twist on a drug used to treat alcohol use disorder could double up as a treatment for stroke, the ...

Home April 14, 2023
Home
News | Pharmaceuticals

April 3, 2023 — Esperion announced the full results from the landmark Cholesterol Lowering via Bempedoic acid, an ACL ...

Home April 03, 2023
Home
News | Pharmaceuticals

April 3, 2023 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

Home April 03, 2023
Home
News | Pharmaceuticals

February 27, 2023 — Amarin Corporation plc announced that data evaluating the role of VASCEPA /VAZKEPA (icosapent ethyl) ...

Home February 27, 2023
Home
News | Pharmaceuticals

November 28, 2022 – Tenaya Therapeutics, a clinical-stage biotechnology company with a mission to discover, develop and ...

Home November 28, 2022
Home
News | Pharmaceuticals

October 17, 2022 — Global Health has paid a deadly price for not using simple, low-cost blood pressure lowering drugs ...

Home October 17, 2022
Home
News | Pharmaceuticals

September 6, 2022 — An analysis of more than 12,000 patients has found that the SGLT2 inhibitors dapagliflozin and ...

Home September 06, 2022
Home
News | Pharmaceuticals

September 6, 2022 — Stopping statin treatment early could substantially reduce lifetime protection against heart disease ...

Home September 06, 2022
Home
Subscribe Now